Elsevier Inc.

SHERPA: Unknown

People

  1. Lesokhin
    Lesokhin
  2. Hassoun
    Hassoun
  3. Giralt
    Giralt
  4. Landau
    Landau
  5. Mailankody
    Mailankody
  6. Korde
    Korde
  7. Shah
    Shah
  8. Hultcrantz
    Hultcrantz
  9. Usmani
    Usmani
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (159)
  2. Department of Medicine (159)
  3. Hematologic Malignancies, Division of (159)
  4. Myeloma (159)
  5. Hematologic Malignancies Research (110)
  6. Survivorship Research (90)
  7. Bone Marrow Transplant (78)
  8. Sloan Kettering Institute Postdocs (58)
  9. CTCR Scholars (53)
  10. Epidemiology and Biostatistics (46)
Search Within
  1. "Myeloma"
Formats
  1. Meeting Abstract (114)
  2. Journal Article (27)
  3. Review (13)
  4. Book Section (1)
  5. Conference Paper (1)
  6. Editorial (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (159)
  2. Department of Medicine (159)
  3. Hematologic Malignancies, Division of (159)
  4. Myeloma (159)
  5. Hematologic Malignancies Research (110)
  6. Survivorship Research (90)

More Groups

People
  1. Alexander Lesokhin (78)
  2. Hani Hassoun (73)
  3. Heather Landau (70)
  4. Sergio Giralt (70)
  5. Sham Mailankody (70)
  6. David Chung (62)

More People

Years
  1. 2025 (1)
  2. 2024 (20)
  3. 2023 (31)
  4. 2022 (19)
  5. 2021 (10)
  6. 2020 (22)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (96)
  2. Biology of Blood and Marrow Transplantation (29)
  3. Best Practice and Research: Clinical Haematology (9)
  4. Seminars in Oncology (7)
  5. Transplantation and Cellular Therapy (4)
  6. International Journal of Radiation Oncology, Biology, Physics (3)

More Publications

Results (159)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of BMS-986393 in patients with quadruple-class exposed relapsed or refractory multiple myeloma
    Meeting Abstract

    Patel, K.; Nadeem, O.; Munshi, N.; Iida, S.; Mailankody, S.; Neri, P.; Gregory, T.; Piasecki, J.; Ziyad, S.; Hu, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of ABBV-383, a BCMA bispecific antibody, in black patients with relapsed/refractory multiple myeloma: A subgroup analysis of a phase 1 trial
    Meeting Abstract

    D'Souza, A.; Rodriguez-Valdes, C.; Kumar, S.; Chung, A.; Tuchman, S.; Safah, H.; Weisel, K.; Teipel, R.; Korde, N.; Vij, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)
    Meeting Abstract

    Costa, A.; Dhakal, B.; Hultcrantz, M.; Bal, S.; Chuah, H.; Kaufman, J. L.; Kazandjian, D.; Nathwani, N.; Royle, G.; Sborov, D. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma
    Meeting Abstract

    Thomas, S.; Manasanch, E.; Korde, N.; Lee, H.; Jagannath, S.; Becnel, M.; Kaufman, G.; Patel, K.; Iyer, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; GarceĢs, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save